
Post-exposure COVID shield: new antiviral pill cuts household transmission
A NEJM trial shows the antiviral ensitrelvir (Xocova) significantly reduces COVID-19 risk after exposure in households, cutting symptomatic infections from about 9% to 3% and total infections from 21.5% to 14% when given as a five‑day course. Japan has approved ensitrelvir for post‑exposure use; US/EU decisions are pending. The drug is generally well tolerated and may help vulnerable groups, though real‑world impact may be limited as immunity rises and variants shift.







